Matrixx Bought By Private Equity Firm H.I.G., Settles Personal Injury Lawsuits
This article was originally published in The Tan Sheet
Executive Summary
Matrixx Initiatives announced Dec. 14 private equity firm H.I.G. Capital will acquire the Scottsdale, Ariz.-based maker of Zicam cough/cold products for approximately $75.2 million.
You may also be interested in...
Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO
Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.
Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO
Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.
H.I.G.’s Capstone Puts Customers First With Custom Formulations
The private equity firm’s H.I.G. Growth Partners capital investment affiliate merges two of its businesses, Integrity Nutraceuticals and Cornerstone Research & Development, into Capstone Nutrition. CEO Greg Horn says “we really occupy a niche” in “a pretty fragmented industry” with custom formulations for every product.